$9.50 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Erasca

Erasca, Inc is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company is engaged in oncology and RAS targeting to create therapies and combination regimens for the treatment of cancer. Its product candidates are ERAS-007 and ERAS-601, which together comprises its MAPKlamp. In addition, it also includes two discovery programs, ERAS-9 and ERAS-11, small molecule inhibitor programs targeting SOS1 and MYC, respectively. Its MAPKlamp is an approach targeting upstream and downstream nodes in the RAS/MAPK pathway designed to shut down, or clamp, the signaling of various oncogenic drivers, such as RTKs, NF1, RAS, RAF, and MEK alterations trapped in between any nodes involving this pathway. With its MAPKlamp approach, it induces tumor regression in RAS/MAPK pathway-driven cancers, while also blocking the escape routes that lead to tumor resistance.

Stock Analysis

last close $9.5
1-mo return 41.8%
3-mo return 53.7%
avg daily vol. 294.83T
52-week high 24.47
52-week low 4.51
market cap. $1.1B
forward pe -
annual div. -
roe -95.6%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 74.2%

Subscribe now for daily local and international financial news